Published date: 24 September 2018

Last edited date: 24 September 2018

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 2 October 2018

Contract summary

Industry

  • Administrative healthcare services - 75122000

Location of contract

Any region

Value of contract

£0

Procurement reference

tender_190043/713406

Published date

24 September 2018

Closing date

2 October 2018

Contract start date

8 October 2018

Contract end date

30 November 2018

Contract type

Service contract

Procedure type

Open procedure (below threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements below the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

PHE is conducting a review of the evidence on prescribed drugs that may cause dependence, and the short term discontinuation or longer term withdrawal symptoms,
associated with prescribed medicines.

More information

Additional text

PHE is seeking an organisation with control of existing datasets that include information on the volume of prescribed medicines in the UK, and able to supply data on the volume (by unit) for each of the drugs included in the review that were:
1. issued within care homes in England; or
2. dispensed on private prescriptions from retail pharmacies.

The data would be required by country within the UK (England, Wales, Scotland, Northern Ireland) for the period March 2013 until April 2018 provided in monthly, quarterly and annual illustrations delivered as a single data extract by 30th November 2018.

Costs
The overall contract value will be a maximum of £12,200 (excluding VAT).
A detailed breakdown of costs is required, which will need to demonstrate value for money.

How to apply
Email details of the raw data you are able to provide and quote with breakdown of costs to Michael.Griffin@phe.gov.uk

Drug class (for this analysis) BNF chapter Drugs included
Opioids
4.7.2 Buprenorphine
Codeine*
Dextromoramide
Diamorphine
Dihydrocodeine**
Dipipanone (including with cyclizine)
Fentanyl
Hydromorphone
Meptazinol
Methadone
Morphine (including with cyclizine)
Oxycodone (including with naloxone)
Papaveretum
Pentazocine
Pentazocine
Pethidine
Tapentadol
Tramadol (including with paracetamol)

4.7.1 Codeine with paracetamol = co-codamol*
Dihydrocodeine with paracetamol = co-dydramol**

Z-drugs
4.1.1 Zaleplon
Zopiclone
Zolpidem

Benzodiazepines
4.1.1 (insomnia)
Flurazepam
Loprazolam
Lormetazepam
Nitrazepam
Temazepam
4.1.2 (anxiety)
Diazepam
Chlordiazepoxide
Lorazepam
Oxazepam

Gabapentinoids
4.7.3 Gabapentin

4.8.1 Pregabalin

Antidepressants
4.3.1 (Tricyclics)
Amitriptyline (including with perphenazine)
Amoxapine
Clomipramine
Dosulepin
Doxepin
Imipramine
Lofepramine
Maprotiline
Mianserin
Nortriptyline
Protriptyline
Trazodone
Trimipramine
4.3.2 (MAOIs) Isocarboxazid
Moclobemide
Phenelzine
Tranylcypromine
4.3.3 (SSRIs) Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
4.3.4 (Other antidepressants)
Agomelatine
Duloxetine
Flupentixol
Mirtazapine
Nefazodone
Oxitriptan
Reboxetine
Tryptophan
Venlafaxine
Vortioxetine

About the buyer

Contact name

Michael Griffin

Address

Wellington House, 133-155 Waterloo Road
London
SE1 8UG
England

Email

Michael.Griffin@phe.gov.uk